Financial

The funds will be used for the expansion of the provider and life-science networks, provider and patient engagement teams, and general corporate purposes.

The company will use the money to expand sales and marketing, business development, and customer support, as well as accelerate product development.

The company offers a health sensing device that a baby wears around their ankle to measure heart rate, skin temperature, motion and position.

The company offers a mobile and web-based program that can be prescribed to patients who are taking part in musculoskeletal injury rehabilitation.

The proceeds will be used to continue developing the DigiSight Network and other specialized remote monitoring technologies with an expanded team.

The company provides individual physicians, physician groups, urgent care providers and other practitioners with an integrated telehealth solution.

The San Francisco-based company will use the fresh funds to grow its technical team and continue building its smart glasses technologies for the hospital.

The funds will go towards expanding the availability of Guardant360, the biopsy-free cancer test that identifies critical tumor genomic alterations in real-time.

The company makes care coordination and patient engagement solutions for providers focused on cancer care, congestive heart failure, senior care, and COPD.

The new capital will help underpin the manufacture and launch of a second generation, FDA-cleared, wireless fetal monitoring product.